Lyell Immunopharma Inc. (NASDAQ:LYEL)’s traded shares stood at 1.09 million during the last session. At the close of trading, the stock’s price was $11.66, to imply a decrease of -11.53% or -$1.52 in intraday trading. The LYEL share’s 52-week high remains $19.84, putting it -70.15% down since that peak but still an impressive -12.44% since price per share fell to its 52-week low of $13.11. The company has a valuation of $2.62B, with an average of 1.17 million shares in intraday trading volume over the past 10 days and average of 500.73K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Lyell Immunopharma Inc. (LYEL), translating to a mean rating of 1.70. Of 4 analyst(s) looking at the stock, 0 analyst(s) give LYEL a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.27.
Lyell Immunopharma Inc. (NASDAQ:LYEL) trade information
After registering a -11.53% downside in the last session, Lyell Immunopharma Inc. (LYEL) has traded red over the past five days. The stock hit a weekly high of 18.16 this Thursday, 09/16/21, dropping -11.53% in its intraday price action. The 5-day price performance for the stock is -30.84%, and -20.84% over 30 days. With these gigs, the year-to-date price performance is -30.97%.
Analysts on Wall Street suggest a consensus price target of $25.50, implying an increase of 54.27% to the stock’s current value. The extremes give us $22.00 and $30.00 for target low and target high price respectively. As such, LYEL has been trading -157.29% off suggested target high and -88.68% from its likely low.
Lyell Immunopharma Inc. (LYEL) estimates and forecasts
Revenue forecast for the current quarter as set by 2 analysts is $2.3 million. Meanwhile, for the quarter ending Dec 2021, a total of 2 analyst(s) estimate revenue growth to $2.35 million.
Lyell Immunopharma Inc. has its next earnings report out in October. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Lyell Immunopharma Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Lyell Immunopharma Inc. (NASDAQ:LYEL)’s Major holders
Lyell Immunopharma Inc. insiders hold 3.32% of total outstanding shares, with institutional holders owning 0.00% of the shares at 0.00% float percentage. In total, 0.00% institutions holds shares in the company.